Randomized Study to Compare the Bioavailability of Two Clobetasol Propionate 0.05% Topical Foams

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to compare the relative vasoconstrictive effects of test and reference Clobetasol Propionate 0.05% Topical Foam in healthy, female subjects.

Official Title
-----------------
Bioequivalence of Two Clobetasol Propionate 0.05% Topical Foams

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Clobetasol Propionate 0.05% Foam-Reference Product
* Drug: Clobetasol Propionate 0.05% Foam-Test product


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-tobacco using female subjects, 18 to 50 years of age Demonstrated blanching response to Reference Drug Body Mass Index (BMI) of 30 or less Good health as determined by lack of clinically significant abnormalities in medical history and clinical assessment, as judged by the Investigator Signed and dated informed consent form which meets all criteria of current FDA regulations Exclusion Criteria: History of allergy to systemic or topical corticosteroids Presence on any skin condition or coloration that would interfere with the placement of test sites or the response or assessment of skin blanching Presence of medical condition requiring regular treatment with prescription drugs Drug or alcohol addiction requiring treatment in the past 12 months prior to dosing Use of any tobacco products in the 30 days prior to study dosing Use of any dermatological drug therapy on the flexor surface of the forearms within 30 days of dosing Receipt of any drugs as part of a research study within 30 days prior to study dosing Pregnant or lactating

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort Group 1<br>Subjects number 1 to 20 | Drug: Clobetasol Propionate 0.05% Foam-Reference Product<br>* Small amount applied and evaluated over the course of two days<br>Drug: Clobetasol Propionate 0.05% Foam-Test product<br>* Small amount applied and evaluated over the course of two days<br>|
| Cohort Group 2<br>Subjects number 21 to 40 | Drug: Clobetasol Propionate 0.05% Foam-Reference Product<br>* Small amount applied and evaluated over the course of two days<br>Drug: Clobetasol Propionate 0.05% Foam-Test product<br>* Small amount applied and evaluated over the course of two days<br>|
| Cohort Group 3<br>Subjects number 41 to 60 | Drug: Clobetasol Propionate 0.05% Foam-Reference Product<br>* Small amount applied and evaluated over the course of two days<br>Drug: Clobetasol Propionate 0.05% Foam-Test product<br>* Small amount applied and evaluated over the course of two days<br>|
| Cohort Group 4<br>Subjects number 61 to 80 | Drug: Clobetasol Propionate 0.05% Foam-Reference Product<br>* Small amount applied and evaluated over the course of two days<br>Drug: Clobetasol Propionate 0.05% Foam-Test product<br>* Small amount applied and evaluated over the course of two days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vasoconstriction will be measured by the degree of skin blanching observed after treatment removal using a ChromaMeter |  | Over the course of two days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bioequivalence, Clobetasol Propionate